Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor α complex

Cancer Research

Volumn 61, Issue 9, 2001, Pages 3632-3639

  Liu, H ^a   Lee, E S ^a   De Los Reyes, A ^a   Zapf, J W ^a   Jordan, V C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CONFORMATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE DELETION; GENE MUTATION; GENE SILENCING; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

ALLOSTERIC REGULATION; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN CONFORMATION; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRANSFECTION; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 0035328727     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Nuclear receptor coregulators: Cellular and molecular biology
2. Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor
3. Functional domains of the human estrogen receptor
4. The human estrogen receptor has two independent nonacidic transcriptional activation functions
5. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen
6. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
7. Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription
8. Interaction of proteins with transcriptionally active estrogen receptors
9. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
10. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors
11. AIB 1, a steroid receptor coactivator amplified in breast and ovarian cancer
12. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
13. Regulation by estrogen through the 5′-flanking region of the transforming growth factor α gene
14. Estrogen induction of TGF-α is mediated by an estrogen response element composed of two imperfect palindromes
15. Basic guide to the mechanisms of antiestrogen action
16. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium
17. Effects of raloxifene on bone-mineral density, serum-cholesterol concentrations, and uterine endometrium in postmenopausal women
18. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
19. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
20. Tamoxifen, raloxifene, and the prevention of breast cancer
21. Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms
22. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short-acting antiestrogen LY117018
23. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl) ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity
24. Molecular determinants of tissue selectivity in estrogen-receptor modulators
25. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
26. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial
27. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor
28. Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells
29. Molecular basis of agonism and antagonism in the oestrogen receptor
30. The structural basis of estrogen receptor/co-activator recognition and the antagonism of this interaction by tamoxifen
31. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
32. Molecular mechanism of action at estrogen receptor α of a new clinically relevant antiestrogen (GW7604) related to tamoxifen
33. The estrogen receptor from a tamoxifen-stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain
34. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor α mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor
35. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor
36. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog
37. p300 is a component of an estrogen receptor coactivator complex
38. Indolo[3,2-b]carbazole: A dietary-derived factor that exhibits both antiestrogenic and estrogenic activity
39. The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation
40. Expression of transforming growth factor α (TGF α) in differentiated rat mammary tumors: Estrogen induction of TGF α production
41. Expression of transforming growth factor α and its messenger ribonucleic acid in human breast cancer: Its regulation by estrogen and its possible functional significance
42. The human transforming growth factor α promoter directs transcription initiation from a single site in the absence of a TATA sequence
43. Transcriptional activation of transforming growth factor α by estradiol: Requirement for both a GC-rich site and an estrogen response element half-site
44. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER
45. The interaction of raloxifene and the active metabolite of the antiestrogen EM800 (SC5705) with the human estrogen receptor (ER)
46. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors
47. Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor
48. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator
49. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
50. Estrogen receptor activation function 1 works by binding p160 coactivator proteins
51. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors
52. Aspartate 351 of estrogen receptor α is not crucial for the antagonist activity of antiestrogens
53. Peptide antagonists of the human estrogen receptor